Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators plan to see what factors can influence the durability of Exelon patch treatment in Korean patients with Alzheimer's disease.

Based on these results, the investigators will find the ways to maximize the effect and durability of Exelon patch on Korean patients with Alzheimer's disease.

After finishing this study, the investigators are going to present the study results at the international and national academic meetings or conferences.

Also the investigators expect that they can publish the result in a journal of in the field of neurology or dementia till the winter of 2010.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborators: Bobath Memorial Hospital; Chung-Ang University Hosptial, Chung-Ang University College of Medicine; Dong-A University Hospital; Ewha Womans University; Hallym University Medical Center; Hanyang University; Hanyang University Seoul Hospital; Inha University Hospital; Inje University; Jeju National University; Konyang University Hospital; Korea University; Kwandong University Myongji Hospital; Kyunghee University Medical Center; Pusan National University Hospital; Seoul National University Bundang Hospital; Seoul St. Mary's Hospital; SungAe General Hospital; Wonkwang University Sanbon Medical Center; Yong-in Hyoja Geriatric Hospital
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

• Probable AD by NINCDS-ADRDA and DSM-IV

• Male and female aged from 51 to 85 years old

• Magnetic resonance imaging or computed tomographic scan within 12 months consistent with a diagnosis of probable AD

• Patients who approved to release of personal information

Exclusion Criteria:

• Patient with any active pulmonary, gastrointestinal, renal, hepatic (severe hepatic function impaired patients), endocrine, or cardiovascular disease, clinically significant laboratory abnormalities, or any medical condition which would prohibit them from completing the study

• Any patients suspicious of drug addiction or alcohol addiction for the past 10 years

• Any other patients to be decided to be inappropriate for the study by the investigators